Etentamig

DB17268InvestigationalProtein Based Therapies

TNB-383B is a CD3 and B-cell maturation antigen T-cell engaging bispecific antibody.

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 17 and T-cell surface glycoprotein CD3
Curator reviewed
Also known as: Anti-BCMA x aCD3 T-BsAb TNB-383B · Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383
Code names: ABBV-383 · TNB-383B

Resolves to

Compound

Targets

What you can answer from here — as of May 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Etentamig, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.